Dendritic Cells and Antigen Presentation

Why dendritic cells matter

• They decide whether you mount an immune response at all. The adaptive immune system is exquisitely powerful but blind — a naive T cell cannot act until a dendritic cell shows it a specific peptide together with a "danger" signal. Delete dendritic cells (as in CD11c-DTR mouse models) and priming of CD4 and CD8 responses to most pathogens collapses. The dendritic cell is the gatekeeper.
• They are the bridge between innate and adaptive immunity. Dendritic cells read the innate alarm — pathogen-associated molecular patterns detected by Toll-like receptors, RIG-I, NOD, and C-type lectins — and translate it into an instruction set for the adaptive system: which antigen, and which flavor of response (Th1, Th2, Th17, Tfh, or tolerance). No other cell integrates both worlds so directly.
• They enforce peripheral tolerance. In the resting steady state, dendritic cells continuously present harmless self-antigens and food/commensal antigens without costimulation, which deletes or anergizes self-reactive T cells and generates regulatory T cells. This is why we do not attack our own gut microbiome or dietary proteins. Tolerance is the default; immunity is the exception that danger unlocks.
• They make cross-presentation — and therefore anti-viral and anti-tumor killing — possible. A tumor or a virus that never infects a dendritic cell can still be attacked, because the cDC1 subset can route captured antigen onto MHC class I to prime CD8+ cytotoxic T cells. This one trick underpins most cancer immunotherapy.
• They are a therapeutic platform. Sipuleucel-T (Provenge), the first FDA-approved therapeutic cancer vaccine (2010), is a dendritic-cell-based product. mRNA and adjuvanted vaccines work by loading and maturing dendritic cells. Steinman treated his own pancreatic cancer with a dendritic-cell vaccine he designed.
• They are rare but far-reaching. Dendritic cells make up well under 1% of blood mononuclear cells, yet a handful of them in a lymph node can orchestrate a response involving millions of T cells. Their branched morphology maximizes surface area for scanning: one dendritic cell simultaneously contacts many T cells at once.

Common misconceptions

• "Dendritic cells are just a kind of macrophage." They share a myeloid origin and both engulf material, but they are functionally distinct. Macrophages are optimized to destroy and clean up; dendritic cells are optimized to preserve antigen for presentation and to prime naive T cells. A macrophage rarely, if ever, ignites a primary T-cell response; a dendritic cell routinely does.
• "MHC class II is only on dendritic cells." MHC-II is expressed by all professional antigen-presenting cells (dendritic cells, macrophages, B cells) and can be induced on other cells by IFN-γ. What is special about dendritic cells is the combination — high constitutive MHC-II plus costimulation plus lymph-node positioning — not MHC-II alone.
• "Antigen presentation and T-cell activation are the same event." Presentation (signal 1) is necessary but not sufficient. Without costimulation (signal 2), the same peptide-MHC that would activate a T cell instead tolerizes it. This is why a dendritic cell must mature before it can prime — an immature dendritic cell presenting self-peptide induces tolerance, not immunity.
• "Cross-presentation just means presenting to both T-cell types." No — cross-presentation specifically means loading exogenous (engulfed, extracellular) antigen onto MHC class I, breaking the normal rule that MHC-I shows only endogenous cytosolic peptides. It is a distinct, specialized trafficking feat, largely restricted to the cDC1 subset.
• "The dendritic cell moves to the T cell it needs." It cannot search for a specific clone across the body. Instead the dendritic cell migrates to a fixed meeting place — the T-cell zone of the draining lymph node — and lets recirculating naive T cells stream past it. The system works by concentrating both partners in one anatomical location, not by targeted search.
• "All dendritic cells are the same." There are conventional cDC1 (cross-presenting, BATF3/IRF8-dependent, prime CD8 responses), conventional cDC2 (prime CD4 responses, drive Th2/Th17), plasmacytoid dendritic cells (specialized interferon factories in antiviral defense), and monocyte-derived dendritic cells that appear during inflammation. Langerhans cells of the epidermis are a further specialized, self-renewing population.

How dendritic cells present antigen, step by step

The life of an antigen-presenting dendritic cell runs as a spatial program: sample in the tissue, mature on danger, migrate to the node, present, and prime. Sampling. An immature dendritic cell resident in the skin (as a Langerhans cell or dermal dendritic cell), gut lamina propria, or airway is built to capture. It performs constitutive macropinocytosis — drinking bulk extracellular fluid at a rate of up to roughly 1,000 times its own volume per hour — plus receptor-mediated endocytosis via C-type lectins (DC-SIGN, DEC-205, the mannose receptor, CLEC9A for dead-cell debris), and phagocytosis of whole microbes and apoptotic cells. At this stage it holds antigen but is a poor stimulator: MHC-II and costimulatory molecules are low, and captured antigen is stored in intracellular MHC-II compartments rather than fully displayed.

Sensing danger and maturing. Pattern-recognition receptors — Toll-like receptors (TLR4 for LPS, TLR3 for double-stranded RNA, TLR9 for CpG DNA, and others), plus cytosolic RIG-I and NOD sensors — detect conserved microbial signatures. Engagement triggers a maturation switch: the dendritic cell downregulates endocytosis and tissue-retention receptors, stabilizes and floods its surface with peptide-loaded MHC class II, upregulates the costimulatory molecules CD80 and CD86, secretes polarizing cytokines such as IL-12, and — critically — switches on the chemokine receptor CCR7.

Processing and loading. Meanwhile the captured protein is degraded in acidifying endosomes and lysosomes by cathepsin proteases into peptides of roughly 13 to 25 residues. Newly synthesized MHC class II leaves the endoplasmic reticulum with its groove blocked by the invariant chain; proteolysis trims the invariant chain to a residual fragment called CLIP, and the chaperone HLA-DM then catalyzes CLIP release and exchange for a high-affinity antigenic peptide. For cross-presentation, cDC1 dendritic cells divert engulfed antigen either into the cytosol for proteasomal processing and TAP-dependent loading onto MHC class I (the cytosolic pathway) or load it within a specialized endosome (the vacuolar pathway) — arming CD8+ cytotoxic T cells against pathogens and tumors the dendritic cell was never infected by.

Migration. CCR7 makes the maturing dendritic cell chemotactic toward CCL19 and CCL21, chemokines laid down by lymphatic endothelium and by the fibroblastic reticular network of the lymph-node T-cell zone. The cell enters an afferent lymphatic and travels to the draining node over roughly 12 to 48 hours, arriving in the paracortex where naive T cells continuously recirculate. Priming. There it extends its dendrites and screens streaming T cells — thousands per hour — until a rare clone's T-cell receptor engages the displayed peptide-MHC. Now it delivers the three signals: signal 1 (peptide-MHC to the TCR), signal 2 (CD80/CD86 to CD28), and signal 3 (polarizing cytokines such as IL-12). The naive T cell forms a stable immunological synapse, clusters its receptors, and — over a day or two of contact and repeated engagements — commits to proliferation and differentiation into armed effector cells. Innate detection has become adaptive immunity.

Dendritic cell vs macrophage vs B cell as antigen presenters

Feature	Dendritic cell	Macrophage	B cell
Primary job	Prime naive T cells	Phagocytose & destroy	Make antibody
Prime a naive T cell?	Yes — professional, potent	Poorly / rarely	Poorly (needs cognate help)
Antigen capture	Macropinocytosis, lectins, phagocytosis	Phagocytosis (broad, high-capacity)	BCR-specific uptake only
MHC-II level	High, constitutive (rises on maturation)	Inducible (IFN-γ)	Constitutive
Costimulation (CD80/86)	High on mature DC	Low / inducible	Inducible
Cross-presentation on MHC-I	Yes (cDC1 specialists)	Limited	No
Migrates to lymph node?	Yes — CCR7-driven from tissue	Largely tissue-resident	Resides in follicles
Main role in tolerance	Central — deletes/anergizes, makes Tregs	Minor	Minor

MHC class I vs class II presentation

Property	MHC class I	MHC class II
Presents to	CD8+ cytotoxic T cells	CD4+ helper T cells
Peptide source	Endogenous / cytosolic (proteasome)	Exogenous / endocytosed (cathepsins)
Peptide length	~8–10 residues (closed groove)	~13–25 residues (open groove)
Loading location	Endoplasmic reticulum, via TAP	Endosome / MIIC, via HLA-DM
Chaperone / placeholder	Tapasin, calreticulin	Invariant chain → CLIP → HLA-DM
Expression	Nearly all nucleated cells	Professional APCs (DC, macrophage, B cell)
Dendritic-cell twist	Cross-presentation loads exogenous antigen here	Constitutive, high — the DC's main output

Famous experiments and history

• Steinman and Cohn (1973). Ralph Steinman and Zanvil Cohn described a novel, large, stellate cell in mouse peripheral lymphoid organs in the Journal of Experimental Medicine, naming it "dendritic" for its tree-like processes. Over the following decade Steinman showed these rare cells were 100-fold or more potent than any other cell at stimulating T cells in the mixed lymphocyte reaction — a claim initially met with deep skepticism.
• The mixed lymphocyte reaction. By purifying dendritic cells and titrating them into allogeneic T-cell cultures, Steinman's group demonstrated that a handful of dendritic cells could drive massive T-cell proliferation, establishing them as the primary accessory cell of adaptive immunity and distinguishing them functionally from macrophages.
• The two-signal model, made concrete. Building on Bretscher and Cohn's 1970 two-signal hypothesis, work through the 1980s–90s identified CD80/CD86–CD28 as the costimulatory axis and showed that dendritic-cell maturation is what couples signal 2 to signal 1 — explaining how the same cell can induce tolerance when immature and immunity when mature.
• Cross-presentation and the cDC1 lineage. The discovery that the BATF3/IRF8-dependent cDC1 subset (marked by XCR1 and CLEC9A) is specialized to cross-present exogenous antigen onto MHC-I explained how CD8+ killer responses arise against tumors and non-infecting viruses, and made cDC1 a central target in cancer immunotherapy.
• Sipuleucel-T and the 2011 Nobel Prize. Sipuleucel-T (Provenge) became the first FDA-approved therapeutic cancer vaccine in 2010, built on the dendritic-cell/APC principle. In 2011 Ralph Steinman received the Nobel Prize in Physiology or Medicine for the discovery of dendritic cells — announced three days after he died of pancreatic cancer, which he had been treating with a dendritic-cell-based vaccine of his own design.